<DOC>
	<DOCNO>NCT00914043</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related fatigue . PURPOSE : This research study look biological marker fatigue woman residual invasive breast cancer enrol clinical trial NSABP-B-45 .</brief_summary>
	<brief_title>Studying Biological Markers Fatigue Women With Residual Invasive Breast Cancer Enrolled Clinical Trial NSABP-B-45</brief_title>
	<detailed_description>OBJECTIVES : - To collect serial blood specimen time point quality life patient-reported outcome assessment perform woman residual invasive breast cancer concurrently enrol participate Behavioral Health Outcomes component clinical trial NSABP-B-45 . - To prepare , separate , store blood specimen NSABP Serum Bank Baylor College Medicine Breast Center components future DNA , RNA , plasma analysis . - To analyze specific proinflammatory cytokine , genetic polymorphism , RNA expression array collaborate laboratory University California , Los Angeles ( UCLA ) . - To examine association marker inflammation symptom fatigue among patient treat sunitinib malate placebo clinical trial NSABP-B-45 . - To examine relationship single-nucleotide polymorphism promoter region IL-1 IL-6 symptom fatigue patient . - To examine relationship RNA expression profile fatigue compare pattern expression patient . OUTLINE : This multicenter study . Patients undergo blood sample collection* baseline 3 , 6 , 12 , 18 , 24 month analysis plasma concentration inflammatory biomarkers ( IL-1ra , sTNFRII , sIL-6R , C-reactive protein ) ELISA ; DNA polymorphisms promoter region IL-6 IL-1 TaqMan PCR ; RNA gene expression signal pathway RT-PCR assay microarray . NOTE : *Blood sample collect time point Behavioral Health Outcomes quality life patient-reported outcome questionnaire complete clinical trial NSABP-B-45 .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis residual invasive breast cancer Stage II , IIIA , IIIB disease HER2/neunegative disease Randomized receive either sunitinib malate placebo clinical trial NSABPB45 Has start therapy clinical trial NSABPB45 Has complete baseline Behavioral Health Outcome questionnaires clinical trial NSABPB45 Hormonereceptor status specify PATIENT CHARACTERISTICS : Menopausal status specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>fatigue</keyword>
	<keyword>HER2-negative breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>